Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAMOND Study of ALT-711 in Diastolic Heart Failure
NCT00043836Phase 2Completed
- Sponsor
- Synvista Therapeutics, Inc.
- Start
- Jul 2002
- Primary completion
- Feb 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alagebrium in heart failure with preserved ejection fraction (HFpEF), sponsored by Synvista Therapeutics, Inc.. Started Jul 2002; status: completed.
02
Drugs
alagebrium
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT00043836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00043836.